Cohort study of somatostatin-based radiopeptide therapy with [ 90Y-DOTA]-TOC versus [ 90Y-DOTA]-TOC plus [ 177Lu-DOTA]-TOC in neuroendocrine cancers

Journal of Clinical Oncology

Volumn 30, Issue 10, 2012, Pages 1100-1106

  Villard, Linda ^a   Romer, Anna ^a   Marincek, Nicolas ^a   Brunner, Philippe ^a   Koller, Michael T ^a   Schindler, Christian ^b   Ng, Quinn K T ^a   Mäcke, Helmut R ^a   Mul̈er Brand, Jan ^a   Rochlitz, Christoph ^a   Briel, Matthias ^a,c   Walter, Martin A ^a,d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CREATININE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; TETRAXETAN OCTREOTIDE[3 TYROSINE] LUTETIUM 177; TETRAXETAN OCTREOTIDE[3 TYROSINE] YTTRIUM 90; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DISEASE DURATION; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HISTOLOGY; HUMAN; ISOTOPE LABELING; LEUKOPENIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOPROLIFERATIVE DISORDER; NEPHROTOXICITY; NEUROENDOCRINE CANCER; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; SURVIVAL PREDICTION; THROMBOCYTOPENIA; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY; LUTETIUM; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ODDS RATIO; ORGANOMETALLIC COMPOUNDS; RADIOISOTOPES; SOMATOSTATIN; YTTRIUM RADIOISOTOPES;

EID: 84861331197     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.2151     Document Type: Article

References (25)

1. Yao JC, Hassan M, Phan A, et al: One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063-3072, 2008
2. Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427, 2003
3. Oberg K: Cancer: Antitumor effects of octreotide LAR, a somatostatin analog. Nat Rev Endocrinol 6:188-189, 2010
4. Rinke A, Müller HH, Schade-Brittinger C, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 27:4656-4663, 2009
5. Krenning EP, Bakker WH, Breeman WA, et al: Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1:242-244, 1989
6. Otte A, Mueller-Brand J, Dellas S, et al: Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351:417-418, 1998 (Pubitemid 28064170)
7. Imhof A, Brunner P, Marincek N, et al: Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90YDOTA]- TOC in metastasized neuroendocrine cancers. J Clin Oncol 29:2416-2423, 2011
8. Otte A, Jermann E, Behe M, et al: DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 24:792-795, 1997 (Pubitemid 27356860)
9. Otte A, Herrmann R, Heppeler A, et al: Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 26:1439-1447, 1999 (Pubitemid 29515605)
10. Iten F, Müller B, Schindler C, et al: Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: A phase II clinical trial. Clin Cancer Res 13:6696-6702, 2007 (Pubitemid 350206806)
11. Iten F, Muller B, Schindler C, et al: [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: Long-term results of a phase 2 clinical trial. Cancer 115:2052-2062, 2009
12. National Cancer Institute, Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events, Version 3.0. http://www .eortc.be/services/doc/ctc/ctcaev3.pdf
13. Klahr S, Levey AS, Beck GJ, et al: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease: Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877-884, 1994 (Pubitemid 24094966)
14. National Kidney Foundation: Clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. http://www.kidney. org/professionals/kdoqi/pdf/ckd-evaluation-classification- stratification.pdf
15. Putter H, Fiocco M, Geskus RB: Tutorial in biostatistics: Competing risks and multi-state models. Stat Med 26:2389-2430, 2007 (Pubitemid 46730255)
16. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
18. Siegel JA, Stabin MG: Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med 35:152-156, 1994 (Pubitemid 24018459)
19. de Jong M, Breeman WA, Valkema R, et al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 46: 13S-17S, 2005 (suppl 1)
20. Oberg K: Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 12:S111-S114, 2001 (suppl 2)
21. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523, 2011
22. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
23. Waldherr C, Pless M, Maecke HR, et al: The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 12: 941-945, 2001 (Pubitemid 32725766)
24. Vegt E, de Jong M, Wetzels JF, et al: Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 51:1049-1058, 2010
25. Waldherr C, Pless M, Maecke HR, et al: Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43:610-616, 2002 (Pubitemid 34507110)